Decitabine

For research use only.

Catalog No.S1200 Synonyms: Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine

69 publications

Decitabine Chemical Structure

Molecular Weight(MW): 228.21

Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS). Decitabine induces cell cycle arrest and apoptosis in various cancer cell lines.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 155 In stock
USD 90 In stock
USD 170 In stock
USD 320 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Decitabine has been cited by 69 publications

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS). Decitabine induces cell cycle arrest and apoptosis in various cancer cell lines.
Targets
DNA methylation [1]
(HL-60, KG1a cells)
In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 NHzrR5BHfW6ldHnvckBCe3OjeR?= MmTSNE42yqEQvF2= MUmyOEBp MVX3ZZRmeg>? Ml\JcY9lfWyjdHXzJJRp\SCpZX7lJIV5eHKnc4Ppc44hd2ZiTVHHSU1CKG2nbXLldpM> MVKyOVEzOzB6Mh?=
Eca109 NHz1d4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HEUVAvPS9{LkWvOUDPxE1? M1yxS|I1NzR6L{eyJIg> NYKwS|RNf2G2ZYK= MY\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJIRwe2VvIHHu[EB1cW2nLTDk[ZBmdmSnboSgcYFvdmW{ NXL3SFRFOjVzMkOwPFI>
Eca109 NWHwVmQ6TnWwY4Tpc44hSXO|YYm= MorPNE42yqEQvF2= MYW2M|EzNzJ2IHi= MUX3ZZRmeg>? M1HzUYlvcGmkaYTzJINmdGxibXnndoF1cW:wwrC= NFnrRVAzPTF{M{C4Ni=>
Eca109 M{[2eWZ2dmO2aX;uJGF{e2G7 NX;td3VbOC53wrFOwG0> M17mblI1KGh? MWr3ZZRmeg>? NV[zTVg3cW6qaXLpeJMh[2WubDDpcpZie2mxbh?= MV2yOVEzOzB6Mh?=
Eca109 NWfZOpZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2CwUVAvPcLizszN M3ewe|I1KGh? NYD0Om9Uf2G2ZYK= NEDIeWVqdmS3Y3XzJGczN01iYYLy[ZN1KGmwIITo[UBk\WyuIHP5Z4xm NXH5NGtZOjVzMkOwPFI>
Eca109 MYfGeY5kfGmxbjDBd5NigQ>? MYCwMlUwOSEQvF2= NGfnWGIzPCCq NUDrO41wf2G2ZYK= M{XoeIRm[3KnYYPld{BmgHC{ZYPzbY9vKG:oIF7GMe67SjJiYX7kJG1OWDJ? NHy5TIUzPTF{M{C4Ni=>
SW1116  M336SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvxNE42NzFxMj:1JO69VQ>? Ml6wOFghcA>? M1:1fGROW09? M2[4eoVvcGGwY3XzJJRp\SCJZX\peIlvcWJiaX7keYNm\CClZXzsJIlvcGmkaYTpc44> NUXoNINEOjR6N{SyPFY>
LOVO MknzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPnPG0xNjVxMT:yM|Uh|ryP MUe0PEBp M2XoRWROW09? NF7tNphmdmijbnPld{B1cGViR3XmbZRqdmmkIHnu[JVk\WRiY3XscEBqdmirYnn0bY9v NI\oe5QzPDh5NEK4Oi=>
SW1116  M2GzVWZ2dmO2aX;uJGF{e2G7 M3TnN|ExKM7:TR?= M33WUVQ5KGh? NH\COI5FVVOR NYriTY9ScW6lcnXhd4V{KHSqZTDl[oZm[3SrdnWgZZQhcW6qaXLpeIlv\yCDS2SgZY5lKG2WT2Kgd4lodmGuaX7nJJBifGi5YYnzJINwdWKrbnXkJJdqfGhiZ3XmbZRqdmmk MkLMNlQ5PzR{OE[=
LOVO MmLRSpVv[3Srb36gRZN{[Xl? MlnONVAh|ryP NH3UWZM1QCCq NGSzWFZFVVOR MXLpcoNz\WG|ZYOgeIhmKGWoZnXjeIl3\SCjdDDpcohq[mm2aX7nJGFMXCCjbnSgcXRQWiC|aXfuZYxqdmdicHH0bJdigXNiY3;tZolv\WRid3n0bEBo\W[rdHnubYI> NHu5UIUzPDh5NEK4Oi=>
SW1116  Ml\SRZBweHSxc3nzJGF{e2G7 MWKxNEDPxE1? Ml\GOFghcA>? NIPhVVFFVVOR Mnfj[Y5p[W6lZYOgS4VncXSrbnniMYlv\HWlZXSgZZBweHSxc3nz MmThNlQ5PzR{OE[=
LOVO NU\Ge|VOSXCxcITvd4l{KEG|c3H5 M2\YdVExKM7:TR?= M1LIWVQ5KGh? Ml7pSG1UVw>? NUDBZ4Zs\W6qYX7j[ZMhT2WoaYTpcoljNWmwZIXj[YQh[XCxcITvd4l{ MnTRNlQ5PzR{OE[=
RPMI-8226 MmnWRZBweHSxc3nzJGF{e2G7 NIr0RnQyNzJizszN MWW0PE84Oi97NjDo Ml;tSG1UVw>? MkXlbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NFrIVFczPDh|M{GwPC=>
OPM-2  MXrBdI9xfG:|aYOgRZN{[Xl? NGjKOooyNzJizszN NYHPbpRJPzJxOU[vNVIxKGh? MV7EUXNQ NWG3S|hGcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NHfVTHEzPDh|M{GwPC=>
JJN3  NWXLc3NQSXCxcITvd4l{KEG|c3H5 MmTINE42NzFizszN NYLUXIFJOjRxNEigbC=> MkSzSG1UVw>? NHL1OmlqdmS3Y3XzJINmdGxiYYDvdJRwe2m| M{jaSlI1QDN|MUC4
NCI-H929  NUmyXJJmSXCxcITvd4l{KEG|c3H5 MniwNU8zKM7:TR?= NXXBdJh6PzJxOU[vNVIxKGh? MoPISG1UVw>? M17mbIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NX[zcoxMOjR6M{OxNFg>
RPMI-8226 NX\TWFVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3VNU8zKM7:TR?= MojrNlQwPDhxN{KgbC=> M4O1N2ROW09? MX;h[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? Mn3rNlQ5OzNzMEi=
OPM-2  MoLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3ne4QyNzJizszN NGrySIUzPC92OD:3NkBp NYnTd3p6TE2VTx?= NFvRW5Zi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= MnywNlQ5OzNzMEi=
JJN3  NWjCUFFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37DU|AvPS9zIN88US=> NYS0O4VDOjRxNEivO|IhcA>? NF3KNmNFVVOR M{HCeoFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 MVyyOFg{OzFyOB?=
NCI-H929  MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nk[|EwOiEQvF2= MoXxNlQwPDhxN{KgbC=> M3q4NmROW09? M3zEeYFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 NF3RPIMzPDh|M{GwPC=>
HeLa M3j0TGtqdmG|ZTDBd5NigQ>? NWPBVZp2U2l;MUCwNQKBmzVyMECg{txOKG[xcjDoSW5VOQ>? NIDKbJYzPDd6MEC5PC=>
HeLa M3rxSGtqdmG|ZTDBd5NigQ>? MoDDT4k:PS54INMxJFAvPSEQvF2g[o9zKGiHTmSy MkXwNlQ4QDByOUi=
HeLa NX;Z[455U2mwYYPlJGF{e2G7 NH3Td25McT1{MT62JOKyKDNwMDFOwG0h\m:{IHjDUnQy NXey[m1OOjR5OECwPVg>
HeLa NYmyZWY2U2mwYYPlJGF{e2G7 M2HB[WtqRTF2LkSgxtEhPC54IN88UUBnd3JiaFPOWFM> NGnPTGIzPDd6MEC5PC=>
NB4 NFXK[XBHfW6ldHnvckBCe3OjeR?= M3vpSlIvPS93L{euOU8yOCEQvF2= M3rJdlI1KGh? M3f2OWROW09? MUjpcoNz\WG|ZXGgeIhmKGW6cILld5Nqd25ib3[gdJJm[3W{c3;yJI1qWi1zMkXh NFH0ZYEzPDR6NEi3NC=>
CD4+ CD25− T  MnrzSpVv[3Srb36gRZN{[Xl? M1P1VlEwPSEQvF2= M1v4[JJm\HWlZWOg[4xw[mGuIFTORUBu\XSqeXzheIlwdg>? MoH5NlQ1PzZ|NkC=
BV-173 MnXkRZBweHSxc3nzJGF{e2G7 MXqwMlI2NzBwNT:wMlc2NzFizszN MonuOFgwPzJxOU[gbC=> NYr2XodEyqCSQmO= MmPIbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy MW[yOFQzOzZzMx?=
ML-1 M3zMZ2Fxd3C2b4Ppd{BCe3OjeR?= M1HHZlAvOjVxMD61M|AvPzVxMTFOwG0> M4HsZVQ5Nzd{L{m2JIg> NFv5WW7DqFCEUx?= MoG4bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy NHzi[JczPDR{M{[xNy=>
HL-60 NFLGOoRCeG:ydH;zbZMhSXO|YYm= MlXoNE4zPS9yLkWvNE44PS9zIN88US=> M{HiZVQ5Nzd{L{m2JIg> MliyxsBRSlN? NUOzXHBbcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz M{j2e|I1PDJ|NkGz
KG-1a NUTxTGpRSXCxcITvd4l{KEG|c3H5 MlG3NE4zPS9yLkWvNE44PS9zIN88US=> M3;OU|Q5Nzd{L{m2JIg> MV1CpHBDWw>? M1vmZ4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> M4jPRlI1PDJ|NkGz
BV-173 NInxSZdHfW6ldHnvckBCe3OjeR?= MlSyNlUxNzVyMH7N MXW0PEBp NWfKVJVoyqCSQmO= NYq1W5R7cW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl M{nD[FI1PDJ|NkGz
CEM MVnGeY5kfGmxbjDBd5NigQ>? NEjzOpAzPTBxNUCwcm0> NXrrc|BtPDhiaB?= NH7RfJXDqFCEUx?= MY\pcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? NGX2bZQzPDR{M{[xNy=>
HL-60 NXK2eZpwTnWwY4Tpc44hSXO|YYm= MXmyOVAwPTBybl2= NYnhTJZoPDhiaB?= M1y3b:KhWEKV MWrpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? MVOyOFQzOzZzMx?=
ML-1 NVHGRmUzTnWwY4Tpc44hSXO|YYm= NIewPGUzPTBxNUCwcm0> M13HTlQ5KGh? MWJCpHBDWw>? NFPKcGRqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= M3LmTlI1PDJ|NkGz
DLD-1 NGTCRYZHfW6ldHnvckBCe3OjeR?= Ml;aNlUxNzVyMH7N MWS0PEBp NGHINYHDqFCEUx?= NW\nV4E4\G9ibn;0JIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= MViyOFQzOzZzMx?=
HCT-116 NEnEeFNHfW6ldHnvckBCe3OjeR?= M1jjWFI2OC93MEDuUS=> NGnh[Xc1QCCq NXjZN|RzyqCSQmO= M1vmPIRwKG6xdDDpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? MoXHNlQ1OjN4MUO=
U937-A/E-9/14/18  NXP2NY91SXCxcITvd4l{KEG|c3H5 Ml3BNE4xOS9yLkGvNU8yOCEQvF2= NIm2NVA1QCCq NXv4VIxKcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NETwd|AzPDNyMES1Oi=>
HT29 Mo\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLTO|IhcA>? MkHsTWM2OD1zNECwxtEyPzlizszN Ml7KNlQyPzJyNkG=
SW48 Mnj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1v0NlczKGh? MlfuTWM2OD1zNT6yxtE3NjJizszN NYW0RlRKOjRzN{KwOlE>
HCT116 NGDNdVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XCcFczKGh? NVTHbpE{UUN3ME2xMlfDuTBwNDFOwG0> M2DtWFI1OTd{ME[x
HepG2 NWLQbFc{TnWwY4Tpc44hSXO|YYm= MmjrNE42NzFizszN M4ixS|I1KGh? MYLEUXNQ NIPM[YN2eC2{ZXf1cIF1\WRidHjlJJJmdGG2aY\lJG9EXE5{IH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= NUjFfFlLOjRzNE[4O|Q>
LS174T M17Q[mZ2dmO2aX;uJGF{e2G7 M4K0c|AvPS9zIN88US=> NVTkR2U6OjRiaB?= NF\HfmRFVVOR NGj4SXJt\WGmIITvJIFvKGmwY4LlZZNmKG:oIF;DWG4zKGyndnXsdy=> MU[yOFE1Pjh5NB?=
HepG2 M37jPGFxd3C2b4Ppd{BCe3OjeR?= MlXoNU8yOC9zMECg{txO NFv0NWo4KGR? NFLIO45FVVOR MX;pcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MVWyOFE1Pjh5NB?=
LS174T Ml\JRZBweHSxc3nzJGF{e2G7 M2TpelEwOTBxMUCwJO69VQ>? M4fJNVch\A>? M3;W[mROW09? MUTpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MVeyOFE1Pjh5NB?=
QBC-939 MWDBdI9xfG:|aYOgRZN{[Xl? MXSxM|ExNzFyMDFOwG0> M4jKTFch\A>? M13tfWROW09? NF3PbYJqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MYqyOFE1Pjh5NB?=
U251 MYLBdI9xfG:|aYOgRZN{[Xl? NGn1U|IyNzFyL{GwNEDPxE1? MV63JIQ> MlLmSG1UVw>? NVO0cINpcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M4izXFI1OTR4OEe0
HL-60 MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnkeY14OSEQvF2= Mn2yOFghcA>? MWrpcoNz\WG|ZYOgS|IueGijc3WgZ4VtdCCocnHjeIlwdg>? NUfidJBJOjRyMECzNlQ>
MDA‑MB‑453 NVPCRXdVTnWwY4Tpc44hSXO|YYm= M1;leVAvOi9zIN88US=> NXPZeo1YPzJiaB?= MW\jZZV{\XNicnWt[ZhxemW|c3nvckBw\iClbHH1[IlvyqBzwrC= Mm\lNlM5PDR{Mki=
HCC1569 NWnGeYxuTnWwY4Tpc44hSXO|YYm= M3vCWVAvOi9zIN88US=> MXW3NkBp MVfjZZV{\XNicnWt[ZhxemW|c3nvckBw\iClbHH1[IlvyqBzwrC= NIDhV|QzOzh2NEKyPC=>
BT‑474 NFTofnhHfW6ldHnvckBCe3OjeR?= NEjkOJMxNjJxMTFOwG0> NITWU3E4OiCq NHL1NVNk[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> M1PiTlI{QDR2MkK4
AGS NF3TW3JCeG:ydH;zbZMhSXO|YYm= MmixOU8yOC9{MD:1NEDPxE1? M2PnWFQ5yqCqwrC= MV7EUXNQ NEfubppqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJnDqA>? NFTrdWkzOzV6Mke4OC=>
A549 MX7BdI9xfG:|aYOgRZN{[Xl? M2DvVlUwOTBxMkCvOVAh|ryP NGH2[5k1QMLiaNMg NWDhbY06TE2VTx?= NULmOVdvcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6yqB? NVLkOGZCOjN3OEK3PFQ>
AGS  NXnhdnJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\NOU8yOC9{MD:1NEDPxE1? M1zE[FQ5yqCqwrC= M{DPV2ROW09? NUO1XmJzcW6mdXPld{BIOi:PIIDoZZNmKGG{cnXzeOKh NVOwZ|E5OjN3OEK3PFQ>
Kasumi-1 MVnBdI9xfG:|aYOgRZN{[Xl? MkHqNE42KM7:TR?= M3zwdFQ5yqCqwrC= NXL4bIs6\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClbz30doVifGWmIIfpeIghXGZvTmCtd4M> NUnYbIpKOjN2OUOzOFg>
OCI-AML3 NH;MSmxCeG:ydH;zbZMhSXO|YYm= NILFNWIzNjVizszN NEGwNIE1QMLiaNMg NUfGN29V\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClbz30doVifGWmIIfpeIghXGZvTmCtd4M> MmnaNlM1QTN|NEi=
MV4-11 NFzLUJZCeG:ydH;zbZMhSXO|YYm= M2jndlIvPSEQvF2= M3XBWlQ5yqCqwrC= M2HFeIRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj MVmyN|Q6OzN2OB?=
NK  M2HtTmN6fG:2b4jpeJkhSXO|YYm= M3rwSVAvODJvMkCg{txO MXy1JIQ> NGm2W3Jl\WO{ZXHz[ZMhfGinIHP5eI9tgXSrYzDhZ5Rqfmm2eTDv[kBPUyClZXzsd{BifCCrboTldo1m\GmjdHWgZ49v[2WwdILheIlwdnNicnXzeYx1cW6pIHnuJIEhXS2|aHHw[YQh\G:|ZfMAl5Jme3CxboPlJIN2en[n M3ntdFI{OzJ6MEi4
NK  M4rn[WFxd3C2b4Ppd{BCe3OjeR?= NIHKTmkxNjB{LUKwJO69VQ>? NUDsTpdzPSCm MWfk[YNz\WG|ZTDOT{Bk\WyuIIDyc4xq\mW{YYTpc44h[W6mII\pZYJqdGm2eTDhd{B1cGViY3;uZ4VvfHKjdHnvckBqdmO{ZXHz[YQ> MoDiNlM{OjhyOEi=
NK  Ml:2SpVv[3Srb36gRZN{[Xl? MXSwMlAyNTJyIN88US=> MkLqOUBl Mn7TZ4F2e2W|IHj5dI9u\XSqeXzheIlwdiCxZjDOT{Bk\WyuczDpckBiKGSxc3ZihLNz\XOyb37z[S=> MoDrNlM{OjhyOEi=
MOLT4/DNR NHzlSHlHfW6ldHnvckBCe3OjeR?= M2rjPVUh|ryP MnjQOEBl M{LwU5Jm\HWlZYOgRWJESjFibWLORUBmgHC{ZYPzbY9v MXiyN|A3ODV5MB?=
Jurkat/DOX MofvSpVv[3Srb36gRZN{[Xl? Mn[yOUDPxE1? NVO3eVhxPCCm MkPndoVlfWOnczDBRmNDOSCvUl7BJIV5eHKnc4Ppc44> M3TLfVI{ODZyNUew
MOLT4/DNR NIfmRpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUK1JO69VQ>? MXK0JIQ> MkTRdoVlfWOnczD0bIUhUUN3MNMgeoFtfWViZn;yJIRifW6xcoXibYNqdiC|ZX7zbZRqfmm2eR?= NVvueJVZOjNyNkC1O|A>
Jurkat/DOX MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLzOUDPxE1? MkLNOEBl MUDy[YR2[2W|IITo[UBKSzVywrD2ZYx2\SCob4Kg[IF2dm:{dXLpZ4lvKHOnboPpeIl3cXS7 NFfvV|MzOzB4MEW3NC=>
ccRCC  NWfofXNVSXCxcITvd4l{KEG|c3H5 MnHsNE4xOS1zMN88US=> MnXPO|IhcA>? NVnad4FuTE2VTx?= MVjoZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v MXyyNlgzPjR4Nx?=
TNBC  MoOzRZBweHSxc3nzJGF{e2G7 M1nWUlAvODFvMUFOwG0> NInSVIw4OiCq MYrEUXNQ NIHN[pRp[XNibXnubY1idCCnZn\lZ5Qhd25iY3XscEBxem:uaX\ldoF1cW:w MWCyNlgzPjR4Nx?=
A498 MWHBdI9xfG:|aYOgRZN{[Xl? M4ezVlAvODFvMUFOwG0> NWnj[nRtPzJiaB?= MWjEUXNQ NIDJXJNqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv Mln0NlI5OjZ2Nke=
KIJ265T NFrveo5CeG:ydH;zbZMhSXO|YYm= M2\LZlAvODFvMUFOwG0> NFuxPVY4OiCq MYTEUXNQ Mn3GbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> NU\D[JROOjJ6Mk[0Olc>
MDA-231 NE\yNmxCeG:ydH;zbZMhSXO|YYm= NUi5XFZROC5yMT2xNO69VQ>? NIjnZ3g4OiCq NH[wSGJFVVOR MXXpcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu MkjnNlI5OjZ2Nke=
BT-20 NHW4RVdCeG:ydH;zbZMhSXO|YYm= MmXVNE4xOS1zMN88US=> NWDs[3pmPzJiaB?= MVHEUXNQ NIT4TmdqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv M2fIUVIzQDJ4NE[3
U937 MnTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2q4[lUuOjBizszN Mn3pNlQwPDhxN{KgbC=> MWnpcoR2[2W|IHGg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgbY4h[SClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy NHvQdHIzOjd4N{CyNS=>
HL60 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TTSVUuOjBizszN M2nCU|I1NzR6L{eyJIg> NVfLZWRDcW6mdXPld{BiKGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? M2TFUVIzPzZ5MEKx
U937 M4\LbWFxd3C2b4Ppd{BCe3OjeR?= MX6xOUDPxE1? Mk\5NlQwPDhxN{KgbC=> MYnpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M4fKW|IzPzZ5MEKx
HL60 M2qwNmFxd3C2b4Ppd{BCe3OjeR?= MXyxOUDPxE1? NFi3[JQzPC92OD:3NkBp MXnpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NX\6O5VHOjJ5NkewNlE>
LS411N  MlrHRZBweHSxc3nzJGF{e2G7 NVflOJFvOC53IN88US=> NUGyW2JXPzJiaB?= M3\CS4lv[3KnYYPld{BH[XNibWLORUBt\X[nbB?= M17DWFIzPDZzNkm1
MDA-MB-231 MkDjRZBweHSxc3nzJGF{e2G7 MV6xNEDPxE1? M13sRVQ5KGh? Mon3doVlfWOnczDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M3vIfVIyQDh5Nkm3
MCF-7  M2D2TmFxd3C2b4Ppd{BCe3OjeR?= NGrueXUyOCEQvF2= M2PMWVQ5KGh? NULufnVuemWmdXPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NVfQd5EyOjF6OEe2PVc>
A375 NWf2T5ViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoruNE42KM7:TR?= Ml3PNU82NzhiZB?= NG\HNpZqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= NHPvU2czOTd7Nk[yNi=>
SKMEL1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPDfWc3OC53IN88US=> MknxNU82NzhiZB?= MVTpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? MW[yNVc6PjZ{Mh?=
SKMEL3 NEHJXYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXOwMlUh|ryP NID6dFMyNzVxODDk MU\pcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? NGH0eYIzOTd7Nk[yNi=>
SKMEL28 NH3XSHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPJSY84OC53IN88US=> MX6xM|UwQCCm NV\LZYpicW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= NXm0b|lYOjF5OU[2NlI>
MeWo NIjrbotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTXNE42KM7:TR?= Mo\xNU82NzhiZB?= NXHsSW1jcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= M{\DSFIyPzl4NkKy
B16 NUnrNZFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHkNE42KM7:TR?= MWSxM|UwQCCm M{Xr[IlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| NVrmVJhNOjF5OU[2NlI>
Ly 1 M2PoN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzsOJc4OjRiaB?= NUPwU5M{UUN3ME23MlMh|ryP MlXHNlE4PzJyNEm=
Ly 7 MmfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrqcWJ{OjRiaB?= NVfiVINWUUN3ME2xNE44KM7:TR?= NFzxOpEzOTd5MkC0PS=>
Su-DHL6 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:4TVI1KGh? Mo\mTWM2OO,:nkKwJO69VQ>? NGPTNpIzOTd5MkC0PS=>
Ly 10 NFLD[3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHocWl3OjRiaB?= MmjxTWM2OO,:nkKwJO69VQ>? NEDPUoUzOTd5MkC0PS=>
RIVA NIH3WHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPJeWtbOjRiaB?= NVXpXJo4UUN3MP-8olIxKM7:TR?= MkHjNlE4PzJyNEm=
Su-DHL2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV6yOEBp NH\LZZRKSzVy78{eNlAh|ryP NUO0U2R4OjF5N{KwOFk>
Ly 1 NIfsU21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XvOFQ5KGh? NUC4fIpuUUN3ME2wMlM1KM7:TR?= MXeyNVc4OjB2OR?=
Ly 7 M3z0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2qyNlQ5KGh? NI\6bnBKSzVyPUCuNFI2KM7:TR?= M{DGcFIyPzd{MES5
Su-DHL6 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkD4OFghcA>? NHHiSGJKSzVy78{eNlAh|ryP NFr0RoozOTd5MkC0PS=>
Ly 10 M17GUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LGdVQ5KGh? NVr1TY04UUN3ME2xMlgh|ryP MXKyNVc4OjB2OR?=
RIVA NHPSNJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYC0WVloPDhiaB?= MlztTWM2OO,:nkKwJO69VQ>? MnrWNlE4PzJyNEm=
Su-DHL2 NGjoU2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIT5TYw1QCCq M2i5dWlEPTB;MUeuOEDPxE1? MY[yNVc4OjB2OR?=
Ly 1 M3fxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFe0TGM4OiCq NWTDZmNUUUN3ME2wMlAyKM7:TR?= MXGyNVc4OjB2OR?=
Ly 7 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\vXFczKGh? Mn[wTWM2OD1yLkCxPEDPxE1? MkDNNlE4PzJyNEm=
Su-DHL6 NEnVdVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFj5c3I4OiCq MYrJR|UxRTFwNjFOwG0> MlqxNlE4PzJyNEm=
Ly 10 NFPVXZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkO1O|IhcA>? NF3w[nBKSzVyPUGuNkDPxE1? MlXLNlE4PzJyNEm=
RIVA M37iRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7nO|IhcA>? MUXJR|Ux97zgMkCg{txO MX2yNVc4OjB2OR?=
Su-DHL2 MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILuOXo4OiCq M1LvfmlEPTB;MUGuNkDPxE1? Ml[2NlE4PzJyNEm=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Survivin / Bcl-2 / p53 / c-Myc / DNMT1; 

PubMed: 26384351     


HL60/ADR and kasumi-1 cells were lysed after treated with 0, 1, 2, 4μM decitabine for 72h, and antibodies against β-actin was used as loading control of whole cell proteins in western blotting. The expression of DNMT1, c-Myc, P53, Bcl-2 and Survivin were determined in AML cells.

p-AKT / AKT / p-GSK3β / GSK3β / p-Myc / Myc / p-P70 / P70 / p-4EBP-1 / 4EBP-1 / PTEN; 

PubMed: 25762617     


Effects of decitabine on the expression of survival pathway proteins at the indicated concentrations.

phospho-p38 / p38 / phospho-NFκB / NFκB; 

PubMed: 26617834     


Decitabine suppressed the phosphorylation of p38 and NF-κB.

p-JAK1 / JAK1 / p-JAK2 / JAK2 / p-STAT3 / STAT3 ; 

PubMed: 26692933     


DAC inhibits the activity of JAK/STAT3 signaling pathway in HL-60 cells. A. HL-60 cells were exposed to 0.2-1.0 μM DAC for 48 h. Cell lysates were prepared and subjected to western blot assay for p-STAT3 (Tyr705 and Ser727) and total STAT3 protein. DAC treatment led to the dephosphorylation of STAT3 both at Tyr705 and Ser727, with moderate effect on total STAT3 protein. B. DAC also down-regulated the expression of p-JAK1 and p-JAK2 as well as total JAK1 and JAK2 in HL-60 cells. The protein expression of STAT3 and JAKs was normalized to that of β-actin and results are representative from three independent experiments.

E-cadherin / N-cadherin / Snail / MMP-2 / MMP-9 / Bcl-2 / Bax; 

PubMed: 28152502     


The protein level of EMT and invasion related proteins E-cadherin, N-cadherin, Snail, MMP-2, MMP-9 and the protein level of the apoptotic-related proteins, BCL-2 and Bax were detected by western blot. β-actin served as a internal control.

26384351 25762617 26617834 26692933 28152502
Immunofluorescence
DNMT1; 

PubMed: 21303982     


Ren-01 cells (low passage number RCC cells) at <40% confluence were treated with decitabine 0.5 μM. DNMT1 was quantified 48 hours later by immuno-fluorescence (green dots). DAPI was used to stain nuclei (blue stain).

E-cadherin / MMP-9; 

PubMed: 28152502     


Immunofluorescence microscopy to identify invasion-promoting molecule MMP-9 and EMT-protective molecule E-cadherin in YES-2 and TE13 cells treated with DAC. 

21303982 28152502
Growth inhibition assay
Cell viability; 

PubMed: 26384351     


Cells were treated with Decitabine for 72 h. Viability was measured by MTT assay in AML cells and patient samples Different AML cells.

26384351
In vivo In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

Protocol

Kinase Assay:[1]
- Collapse

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
Cell Research:[1]
- Collapse
  • Cell lines: HL-60 and KG1a
  • Concentrations: 0-500 nM
  • Incubation Time: 96 hours
  • Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • Dosages: ≤2.5 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 228.21
Formula

C8H12N4O4

CAS No. 2353-33-5
Storage powder
in solvent
Synonyms Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine
Smiles NC1=NC(=O)N(C=N1)C2CC(O)C(CO)O2

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04086238 Completed Drug: Decitabine Healthy EpiDestiny Inc. October 8 2019 Phase 1
NCT04113616 Recruiting Drug: KRT-232|Drug: Cytarabine|Drug: Decitabine Acute Myeloid Leukemia (AML)|Acute Myeloid Leukemia (AML) Secondary to Myeloproliferative Neoplasms (MPN) Kartos Therapeutics Inc. September 25 2019 Phase 1|Phase 2
NCT03828084 Completed Drug: Decitabine Healthy EpiDestiny Inc. April 3 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is S1200 a racemic mixture or a monomer?

  • Answer:

    S1200 is R form

DNA Methyltransferase Signaling Pathway Map

Tags: buy Decitabine | Decitabine supplier | purchase Decitabine | Decitabine cost | Decitabine manufacturer | order Decitabine | Decitabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID